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ABSTRACT Cell response to extracellular cues is often driven by gradients of morphogenetic and chemotactic proteins, and
therefore descriptions of how such gradients arise are critical to understanding and manipulating these processes. Many of
these proteins are secreted in matrix-binding form to be subsequently released proteolytically, and here we explore how this
feature, along with small dynamic forces that are present in all tissues, can affect pericellular protein gradients. We demonstrate
that 1), pericellular gradients of cell-secreted proteins can be greatly ampliﬁed when secreted by the cell in matrix-binding form
as compared to a nonmatrix-interacting form; and 2), subtle ﬂows can drive signiﬁcant asymmetry in pericellular protein
concentrations and create transcellular gradients that increase in the direction of ﬂow. This study thus demonstrates how
convection and matrix-binding, both physiological characteristics, combine to allow cells to create their own autologous
chemotactic gradients that may drive, for example, tumor cells and immune cells into draining lymphatic capillaries.
INTRODUCTION
It is well established that many extracellular mediators induce
signaling via their transcellular gradients rather than their
absolute amounts, such as morphogen gradients driving
morphogenetic processes (e.g., cellular differentiation, cell
polarization, organization, and tissue remodeling (1,2)) and
chemokine gradients directing leukocyte migration (3).
Furthermore, cells can sense exquisitely small transcellular
gradients, some as low as 1% (4). Predicting and under-
standing such cell behaviors therefore requires knowledge of
the factors at play in controlling pericellular protein gradients
(herein referred to simply as morphogen gradients, which will
include chemokines). Gradients can arise from coupled
diffusion-reaction mechanisms that were described by Turing
(5), who showed that stochastic perturbations in diffusion or
reaction rates between competing morphogens could grow
into large-scale asymmetry. The resulting heterogeneous
spatial patterns, which are necessary for the development of
complex organisms, can therefore occur despite homoge-
neous initial conditions and the symmetric nature of diffusion.
Although this paradigm forms the basis of nearly all
morphogenesis models and is useful for describing static
systems with morphogens that are cell-secreted in a well-
deﬁned environment, there are other biophysical factors that
can affect pericellular morphogen distribution in a 3D tissue
environment, such as matrix interactions and subtle intersti-
tial ﬂows. The effects of such biophysical factors on mor-
phogen gradients are poorly understood.
For example, it is now appreciated that many morphogens
are secreted in precursor forms that contain speciﬁc motifs
that bind to components of the extracellular matrix (ECM)
such as collagen, ﬁbrin and glycoaminoglycans (GAGs) (6–
9) to be later released by cell-mediated proteolysis (6,10,11).
Native morphogens such as VEGF165, for example, have
proteolytically cleavable sites that separate the matrix-
binding portion of the protein from the cell-signaling portion
(11). Similar proteins have also been engineered with a
matrix-binding site such that liberation occurs simply by
substrate degradation, resulting in a protein with a small
ECM fragment attached (12,13). Thus, the ECM is an im-
portant source of many morphogens and chemokines, and this
is likely to affect the gradients of active morphogens that can
become established around cells.
In addition to matrix-binding properties of proteins, the
biomechanical environment may also affect pericellular
morphogen distribution. Living biological tissues are dy-
namic, and physical movements such as ambulation, breath-
ing, and cardiac rhythms as well as pressure differentials
within tissue result in interstitial ﬂuid displacement within
the ECM (14). The lymphatic system drains much of this
displaced ﬂuid, and it is estimated that it processes up to 8
liters of lymph per day in the adult human (15), with in-
terstitial ﬂow velocities on the order of 0.1–1.0 mm/s (16–
19). Additionally, in vitro 3D perfused tissue constructs with
interstitial velocities up to 10 mm/s have shown enhanced
morphogenetic responses (20–23). This convection, how-
ever slow, is likely to affect the gradients of proteins with
small diffusion coefﬁcients, even (as we will show) when
diffusion dominates the overall transport distances.
Indeed, we recently found that interstitial ﬂow synergizes
with the matrix-bound growth factor VEGF to drive capillary
formation from a single-celled suspension of endothelial cells
in vitro (21). We proposed a novel mechanism to explain this
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effect: an ampliﬁcation and biasing of free VEGF gradients
that guides cell-cell communication and eventual network
formation. Here we generalize this mechanism and explore
its limits and robustness. Speciﬁcally, we model gradients of
cell-secreted versus ECM-liberated morphogens (via cell-
secreted proteases) under a variety of conditions. We show
that although interstitial ﬂow itself creates substantial asym-
metry in the pericellular concentration proﬁle of a secreted
morphogen, the combination of ﬂow plus matrix-binding of
morphogens enables the formation of transcellular gradients.
This has important and novel implications for directed chemo-
taxis and morphogenesis.
METHODS
Governing equations
The model involved two simulation steps: ﬁrst, establishing hypotheti-
cal pericellular gradients of a cell-secreted protease, such as a matrix
metalloproteinase, and second, using the protease gradient from step 1 to
model the liberation and gradient formation of morphogen from the ECM.
The ﬁrst step was also performed for the cell-secreted morphogen rather than
the protease, to compare relative gradients of cell-secreted versus matrix-
released morphogens under otherwise equivalent conditions. For both of
these models, we used a steady-state convection-diffusion mass balance:
n=Ci ¼ Di=2Ci1Ri; (1)
where v is the velocity ﬁeld around the cell, Ci is the concentration of solute i
(either protease, Cp, or morphogen, Cm), Di is the diffusion coefﬁcient of i
(assumed isotropic and homogeneous), and Ri is generation or disappearance
of i in the matrix. In the case of cell-secreted protease, Rp accounts for
degradation in protease, and in the case of the ECM-released morphogen, Rm
is the generation of morphogen from the bulk according to the proteolytic
liberation of ECM-bound morphogen into a soluble form.
Deﬁning =^ ¼ L=; =^2 ¼ L2=2 vˆ ¼ v=vinlet; Cˆi ¼ Ci=Co, and Co ¼
maximum concentration, Eq. 1 can be nondimensionalized:
Pe vˆ =^Cˆi ¼ =^2Cˆi1RiL
2
Di
; (2)
where the dimensionless Peclet number (Pe) represents the ratio of con-
vective and diffusive transport: Pe ¼ Lvinlet/Di, L ¼ characteristic length
(here, cell radius).
The ﬂuid velocity proﬁle was modeled using Brinkman’s equation for
ﬂow through porous media (24):
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K
v
/
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/
; (3)
where P is the pressure, m is the solute viscosity, and K is the Darcy
permeability of the ECM. Barman and colleagues solved the Brinkman ve-
locity ﬁeld for a sphere (25), and we have adapted this solution for use in our
model. The resulting component velocities in cylindrical coordinates are:
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where r is the radial distance (normalized by the cell radius a) and
s ¼ a=K0:5 . K varies by many orders of magnitude depending on tissue type
(14,26) and state of remodeling or pathology, and in general, K values in
vitro are much higher than those seen in vivo. For these simulations we set K
¼ 1012 cm2, a value between that for in vitro collagen gels (which is on the
order of 1010 to 109 cm2 (27)) and real tissues (which generally range
from 1011 to 1015 cm2, depending on the tissue); however, it should be
noted that the lowest expected K value in vivo (1015 cm2) resulted in
velocity values that were within 2% of that for K ¼ 1012 cm2 (data not
shown), whereas for the highest expected in vitro value (109 cm2) the
maximum velocity differences were 30% but only within a few microns of
the cell. Velocities at coordinates in a plane bisecting the sphere and parallel
to ﬂow were calculated and converted into component velocities and
coordinates in a 2D Cartesian plane for use in the calculation.
We selected inlet velocities ranging from 0.1 to 6.0 mm/s to cover a range
of published in vivo and in vitro interstitial ﬂow velocities (16–23).
Diffusion coefﬁcients Di (Table 1) were calculated by ﬁrst using the rela-
tionship Do ¼ 3600(MW)(0.34), where Do is the diffusion coefﬁcient in free
solution at 23C andMW is the protein molecular weight (28), then adjusting
to 37C using the Stokes-Einstein relationship, and further adjusting to 70%
of that predicted in free solution to account for matrix interactions (28–31).
For the sake of comparison, we considered the diffusion coefﬁcients of the
matrix-binding ligand and cell-secreted protease to be 120 mm2/s and 80
mm2/s, respectively, according to the ranges given in Table 1 for each. The
modeled situations were then classiﬁed according to Peclet number.
Steady-state assumption
Our goal was to seek ‘‘snapshots’’ of typical pericellular morphogen con-
centrations rather than record the temporal evolution of such patterns. In
justifying the steady-state treatment of the problem we compared the char-
acteristic time constants inherent in the model. Here, the characteristic times
for solute diffusion tdiff and convection tconv over a length scale
Lðtdiff ¼ L2=Di and tconv ¼ L=v ) are both on the order of seconds, whereas
the characteristic time for cell movement over the same length (tcell ¼ L=vcell)
is at least an order of magnitude larger for cells such as ﬁbroblasts, tumor
cells, and endothelial cells (32–34). Thus, we considered the evolution of the
gradients to occur on a short timescale compared to that of the temporal
change of such gradients due to cell movement, and thus the steady-state
assumption is valid for comparing gradient shapes in cell-secreted versus
matrix-released morphogens, or in static versus ﬂow conditions, at a given
instant in time. Of course, true steady state in any biological system would
be difﬁcult to realize because of speciﬁc and dynamic cell response to
receptor-ligand interactions (e.g., receptor internalization and recycling,
etc.); our goal here was to seek generalizable phenomena valid across a
broad range of situations.
Cell release of proteases and morphogens
Cell secretion of any protein is a complex and highly regulated process, but
here we chose two simpliﬁed limiting cases in specifying the cell-secreted
protease boundary conditions. The ﬁrst condition was a constant surface con-
centration, and the other was a constant surface ﬂux. Additionally, the cell
surface was made impermeable to both convective and diffusive ﬂuxes of the
proteases, which were considered noninteracting with the matrix. Morpho-
gens were considered either noninteracting or subject to binding at the cell
surface, allowing us to explore the effects of cell consumption.
Protease decay
Many proteases such as MMPs are heavily regulated posttranslationally by
interactions with tissue inhibitors of metalloproteinases, enzymatic process-
ing, and endocytosis after binding to chaperone molecules (reviewed in
Sternlicht and Werb (35)). However, there is little information about the
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physiological rates at which these inactivation mechanisms take place, and
furthermore, these interactions are likely to be highly speciﬁc to the par-
ticular ECM and protease in question. We assumed the protease degradation
rate was ﬁrst-order such that Rp ¼ kpCˆp (36). To explore and generalize
the effects of decaying protease on relative gradient shapes between ﬂow
versus static conditions and secreted versus matrix-liberated morphogens,
we examined two conditions, kp ¼ 0 s1 and 0.2 s1, the larger value
yielding degradation on the same order of magnitude as the diffusion and
convection terms in Eq. 1.
Matrix-released morphogens
We considered that the morphogen was stored bound to the ECM and lib-
erated to a soluble form only through proteolysis. Under this assumption, the
generation term Rm was used to account for this release and was assumed to
be linearly proportional to the concentration of proteases ðCˆpÞ that were
generated by the cell: Rm ¼ kECMCˆpSˆ , where Sˆ is the dimensionless
concentration of bound morphogen and kECM is the rate constant for lib-
eration of morphogen from the ECM. We ﬁrst assumed that Sˆ was uniform
throughout the ECM and we assigned the product kECMSˆ a value of 1.0 s
1,
making all terms in Eq. 1 of equal importance. The concentration ﬁeld Cˆp
used for the ECM-released morphogen calculation was the steady-state solu-
tion calculated for a cell-secreted protease at the same ﬂow conditions. For
these calculations, the cell was not a source of morphogen and was imper-
meable to convective and diffusive ﬂuxes of the released morphogen. Addi-
tional calculations were performed to explore the cell boundary condition of
morphogen consumption; these are discussed below. The effects of morpho-
gen decay were also explored through the addition of a decay term Rd ¼
kmCˆm in the samemanner as detailed for the decay of proteases listed above.
Nonuniform distribution of
ECM-bound morphogen
In many cases, the matrix-binding form of a morphogen would be secreted
into the ECM by the same cell that would later proteolytically release it, and
thus the initial pericellular distribution of bound morphogen would be
spatially nonuniform. In this case the distribution would depend on the ﬂow
velocity and morphogen diffusion coefﬁcient, and would be essentially
identical (in dimensionless terms) to the distribution of the cell-secreted
proteases under the same ﬂow conditions. The effects of this nonuniform dis-
tribution were examined using the same assumptions as before, i.e.,
Rm ¼ kECMCˆpSˆ , with the only difference being that Sˆ , the matrix-bound
morphogen concentration, was in this case nonuniform and assigned the
same numerical values as the protease concentrations under the various ﬂow
conditions (i.e., Sˆ ¼ Cˆp ), whereas kECM was assigned a value of 1.0 s1.
Consumption of ECM-released morphogens
Although many soluble proteases are readily degraded in the extracellular
environment, some ECM-released morphogens such as VEGF have been
reported to be fairly stable in the ECM (11,36). However, the morphogen
may be consumed through cell binding and internalization. Though the
kinetics of receptor-ligand interactions are highly speciﬁc and dynamic, we
examined the general effects of such cell surface consumption on ﬁnal
morphogen distribution by comparing three different scenarios: no binding,
baseline binding, and exaggerated binding cases. The kinetics were sim-
pliﬁed such that the binding and cell internalization were modeled according
to Consumption ¼ konCreceptorCˆm ¼ keff Cˆm . For the baseline binding case,
we used a speciﬁc example from the literature for VEGF, where keff ¼ 0.4
s1 (37), and assumed that all bound ligands would be internalized to
maximize the effects. For the exaggerated case keff was increased to 1.0 s
1.
Solution algorithm
Equation 1 was numerically solved in two dimensions using a ﬁnite-volume
simulation employing the tridiagonal matrix algorithm. The algorithm was
contained in custom code written for MATLAB 6.5.1 (The MathWorks,
Natick, MA) and was executed on a personal computer. Due to symmetry,
the solution was sought only in a half-domain with the cell being represented
by a semicircular disk 10 mm in radius. There were 43,624 control volumes
in the solution domain (133 in the vertical and 328 in the horizontal) of uni-
form 1-mm2 size. For all solutions, ﬂuid entering the solution domain did not
contain any of the solute. The border of symmetry through the cell centerline
had a no-ﬂux boundary, whereas the other three boundaries were zero
diffusive ﬂux boundaries. A maximum change of calculated concentration of
TABLE 1 Properties of selected morphogens, chemokines, and proteases
Morphogen or
chemokine
Molecular
mass (kDa) Binding substrate Cellular effect
Diffusion
coefﬁcient (mm2/s)
VEGF165 38.2 (dimer) Proteoglycans (6) Fibrin (53) Vascular permeability and
angiogenesis
92
bFGF 18 Fibrin (9) Upregulation of u-PA, u-PAR,
and u-PAI
120
CCL5
CCL17
CCL21
7.5–14 Sulfated GAGs (7) Leukocyte recruitment 130–160
Interleukin-1B 17 Fibrin (8) Upregulation of NO and
chemokines
121
VonWillebrand
factor
20 Fibrin (54)
Collagens and glycoproteins (55)
Platelet adhesion and storage
of factor VIII
115
Endostatin 20 GAGs (56) Angiogenesis inhibitor 115
PEDF 50 GAGs/Collagen (57) Neurotrophic and antiangiogenic 84
Protease Molecular mass(kDa) Speciﬁcity Diffusion coefﬁcient (mm2/s)
u-PA 31–50 Plasminogen 84–97
t-PA 70 Plasminogen 75
Plasmin 92 Fibrin 68
MMP2 64–72 Collagen/gelatin 74–77
MMP3 43–52 Fibrin collagen/gelatin 83–89
MMP9 84–92 Collagen 68–71
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,0.25% for any given control volume between iterations was used as the
convergence criterion.
RESULTS
Directional bias in cell-secreted proteins
For secreted proteins such as proteases or morphogens with
diffusion coefﬁcients in the range of 0–120 mm2/s, we found
that the relevant ranges of interstitial ﬂow of 0.1–6.0 mm/s
can signiﬁcantly bias the pericellular distributions of such
cell-secreted proteins, even with very low Peclet numbers
(Fig. 1). Although many metabolic compounds such as glu-
cose, vitamins, and CO2 have large enough diffusion co-
efﬁcients to be unaffected by physiological ﬂows, most
proteins are large enough (Table 1) that even subtle ﬂows can
cause noticeable biasing in their pericellular distributions.
Creation of transcellular gradients of
matrix-released morphogens
Our data show that the distributions of morphogens that are
proteolytically released from the ECM under ﬂow conditions
exhibit ampliﬁed gradients, with greater asymmetry and
increased downstream ranges than if the same molecules had
been secreted in soluble form by the cell under the same ﬂow
conditions. The two-step calculations whereby proteases se-
creted by the cell in turn liberate morphogens from their
ECM-bound form was examined for a physiological range of
ﬂow conditions (Fig. 2). Transcellular gradients refer to the
percent differences between upstream and downstream mor-
phogen concentrations across the cell (Fig. 2 F), which
determines the extent to which the cell can sense and respond
to the gradient; positive numbers refer to gradients that in-
crease in the direction of ﬂow across the cell. The degree of
ampliﬁcation by matrix-binding was striking: for example,
whereas the transcellular gradient at the highest ﬂow velocity
for the cell-secreted morphogen was only 5%, the corre-
sponding value for the ECM-released morphogen was 133%,
a 26-fold increase. Even the slowest velocity tested (0.12
mm/s) resulted in a marked ampliﬁcation of the transcellular
morphogen gradient when compared to static case (2% vs.
0%), and is between the values of 1%, shown to be adequate
for neutrophil sensing (4), and 10%, suggested to be ade-
quate for ﬁbroblast sensing (38).
This autologous gradient generation can provide the cell
with chemotactic cues and is important, given that chemo-
tactic responses typically occur according to a direction of
increasing chemokine concentration relative to the cell (39).
It is generally assumed that other cells are necessarily the
source of such chemokine gradients. Our results, however,
introduce and demonstrate a mechanism by which a cell can
create an autologous chemotactic gradient even at relatively
low but physiological Peclet numbers. This phenomenon is
not possible at physiological ﬂow rates when the chemokines
are directly cell-secreted in their active forms.
Effect of protease and morphogen decay
Soluble proteases can be inactivated in the pericellular envi-
ronment, and ECM-released morphogens are also susceptible
to inactivation or rebinding to the matrix in the pericellular
environment. For this reason we explored the effects of bulk
degradation terms (Rp, and Rd) for the Pe ¼ 0.25 case, com-
paring the effects of decay of cell-secreted protease, decay of
ECM-released morphogen, and decay of both (Fig. 3). In all
cases, ‘‘decay’’ refers to any mechanism of inactivation of the
soluble form of the protein, whether by chemical inhibitors,
further cleavage, matrix binding, or other mechanisms.
We found that adding these decay terms reduced both the
ﬁnal ECM-released morphogen concentrations and the
transcellular morphogen gradients that could be formed
(Fig. 3). However, these decreases were not drastic (,50%),
and the general result that subtle ﬂow and matrix-binding
properties of morphogen combined to facilitate autologous
transcellular gradients still remained robust. It should be
noted that a decay rate constant of 0.2 s1 was used for both
protease and morphogen decay so that the effect would be
large enough to observe, and although exact values for the
decay constants would vary between individual proteases
and morphogens, the value we used would likely overesti-
mate the effects for ECM-released morphogens. For exam-
ple, decay rates for basic ﬁbroblast growth factor have been
estimated at ;4 orders of magnitude lower than that used
here (36), and a reduction of km for the ECM-released mor-
phogen from 0.2 to 0.01 s1 yielded results that differed from
the nondecay case by ,1% (data not shown). These results
show that decay terms can act to diminish the ampliﬁcation
FIGURE 1 Physiological ranges of ﬂow velocities and diffusion coefﬁ-
cients result in biased cell-secreted morphogen gradients. Typical concen-
tration contours show the trend toward biased gradients as either velocity is
increased or the diffusion coefﬁcient of the secreted protein is decreased.
This biasing occurs for low Peclet numbers (Pe , 1).
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effects of matrix binding, but that autologous transcellular
gradient formation is still a robust phenomenon.
Effects of cell consumption
In addition to protein decay, loss of morphogen may occur
by receptor binding and endocytosis, so we examined the
effects of cell consumption on the overall morphogen
concentration for Pe ¼ 0.25. At the baseline consumption
rate our results showed little effect of cell consumption on
the overall transcellular morphogen gradients (Fig. 3). The
consumption calculations were performed both with and
without decay terms and although generally minimal, the
effects of consumption were the most pronounced when no
other decay terms were included (Fig. 3 E). In the higher
binding case, which was performed to better determine the
qualitative response of this consumption term, the trans-
cellular gradients were again not markedly different com-
pared to the baseline consumption case. The results did
suggest, however, that cell consumption can actually aid in
the formation of downstream gradients that increase with
increasing distance from the cell due to the loss of ligands at
the cell surface. In summary, cell consumption has negligible
effects on transcellular gradients for the conditions tested,
but in general it can increase downstream morphogen gra-
dients to make them positive.
FIGURE 2 Creation and ampliﬁcation of autologous morphogen gradients by subtle physiological ﬂows and matrix-binding properties of morphogen. (A)
Dimensionless concentration gradients of cell-released proteases calculated using a constant surface concentration are increasingly skewed in the direction of ﬂow with
increasing ﬂow velocities. Red, 1 (maximum concentration); dark blue, 0. (B) Dimensionless concentration gradients of liberated morphogen are released from the ECM
through the action of the cell-secreted protease whose proﬁles are shown in A. (C) Distributions of cell-released morphogen demonstrate, when compared with the
corresponding proﬁles in B, the marked gradient ampliﬁcation effect in matrix-released versus cell-secreted morphogen properties under otherwise identical conditions.
(D) Cell-secreted morphogen concentrations as calculated along a line parallel to ﬂow and passing through the cell midlines. All ﬂow conditions result in cell
concentrations that decrease with increasing distance from the cell. (E) ECM-released morphogen concentrations show greater asymmetry compared to those of cell-
secreted morphogens for the same ﬂow conditions. Interestingly, the higher Peclet numbers (0.25 and 0.5) show increasing concentration gradients with increasing
distance downstream from the cell. (F) Calculated transcellular gradients (percentage difference between the downstream and upstream sides of the cell) reveal the degree
of gradient ampliﬁcation that is achieved when morphogen is secreted into matrix-binding form and demonstrate the potential for autologous chemotaxis gradients.
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Effects of boundary conditions on
computed gradients
To determine the effects of boundary conditions on pericel-
lular morphogen proﬁles, both constant surface concentra-
tion and constant ﬂux boundary conditions were compared in
calculating cell-released protease gradients for Pe ¼ 0.25.
Likewise, for ECM-released morphogen gradients, the initial
conditions were varied between uniform and nonuniform
matrix-bound morphogen (see Methods). These two differ-
ent boundary conditions were used to compare two limiting
cases rather than to mimic the actual physiological condition.
Given the complexity of the inherent regulation mechanisms,
either choice of boundary condition is a gross simpliﬁcation
of what is likely in reality a spatially inhomogeneous
phenomenon (and dependent on the details of the particular
protease being secreted), but we considered these two cases
to represent limits or boundaries. In one extreme (constant-
ﬂux BC), the cell would be secreting protease at a constant
rate without any feedback of the external concentration, so
that no matter what the external concentration, the same
amount is constantly being secreted. In the other extreme, the
cell is acutely sensitive to the external concentration of the
secreted protein and it autoregulates secretion according to
what it senses externally.
We saw that the ﬁnal morphogen distribution was
relatively insensitive to the choice of boundary conditions
(Fig. 4). Thus, we concluded that the general phenomenon of
ﬂow-biased and ﬂow-ampliﬁed morphogen gradient forma-
tion is relatively insensitive to what is actually happening at
the cell surface with regard to secretion or receptor ligation.
DISCUSSION
Asymmetry in morphogen gradients is typically described
using diffusion-reaction models under static conditions, but
FIGURE 3 Effect of protein decay on protease and morphogen gradients for Pe ¼ 0.25. Pericellular distributions of cell-secreted protease (top row) and
resulting ECM-released morphogen (bottom row) with (A) no decay, (B) morphogen decay of km¼ 0.2 s1, (C) protease decay of kp ¼ 0.2 s1, and (D) both
protease and morphogen decay kp and km ¼ 0.2 s1. In all cases the ECM-released morphogen concentrations were normalized: dark red, 1 (maximum
concentration); dark blue, 0. (E) Concentrations of ECM-released morphogen as measured along a line passing through the cell midline parallel to ﬂow in each
of the conditions (A–D), each with and without inclusion of a cell consumption term. keff was varied between 0 s
1 (solid lines), 0.4 s1 (thick dotted lines), and
1.0 s1 (thin dotted lines). (F) Calculated transcellular gradients were reduced in magnitude by the decay considerations, and cell consumption affected the
gradients by negligible amounts; however, in all cases the transcellular gradients still increased in the direction of ﬂow, and remained well above
physiologically detectable levels of 1–10%.
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living systems are dynamic, low levels of interstitial ﬂow are
ubiquitous, and many secreted morphogens are bound to the
matrix to be later released. Furthermore, nature hints at a role
of ﬂow in directing morphogenesis; for example, convection
of amniotic ﬂuid has been shown to help determine left/right
asymmetry in developing mouse embryos (40), and intersti-
tial ﬂuid ﬂow was demonstrated to guide lymphangiogenesis
in a wound-healing model (41) and drive blood and lym-
phatic capillary morphogenesis in vitro (20,21). With these
examples as guides, we have developed a model that shows
how the combination of ECM-binding morphogens and
interstitial ﬂow can provide cells with developmental cues in
the form of strong autologous transcellular gradients. In its
general form, our model is not used to predict speciﬁc
gradients that would arise from any particular morphogen
situation, but rather to demonstrate the general phenomenon
of autologous morphogen and chemokine gradient formation
and ampliﬁcation via matrix-binding morphogen properties
coupled with very subtle dynamic forces. The minimum
transcellular difference in morphogen concentration required
for cell recognition varies by cell type and morphogen/
receptor system. Morphogens can signal through several
families of receptors such as tyrosine kinases and G-protein
coupled receptors and each involves its own cascade and
intercellular ampliﬁcation system (reviewed in Kholodenko
(42)). These intracellular ampliﬁcation systems allow cells to
create large internal gradients of response molecules such as
AKT protein kinase in response to much shallower extra-
cellular signaling gradients. Minimum required external
gradient thresholds range from as low as 1% for neutrophil
sensing (4) to levels on the order of 10% or more for
ﬁbroblasts (38). Although 1% autocrine morphogen gradi-
ents are possible due to interstitial ﬂow alone (Fig. 2 F), a
transcellular gradient of 10% or more is not possible for a
cell-secreted morphogen under physiological ﬂow rates
alone, but rather only when combined with matrix-binding
characteristics of the morphogen. Whatever the minimum
threshold required for a given cell/morphogen pair may be,
ECM binding can result in up to 25-fold ampliﬁcation over
directly secreted morphogens.
Our results have intriguing implications for chemotactic
processes. It is well known that both metastatic tumor cells
and activated immune cells trafﬁc in the lymphatic system
(43,44), but exactly how these cells efﬁciently migrate
through the tissue matrix toward the nearest lymphatic
vessel is not known. Both cell types migrate up gradients of
the chemokines CCL21 and CCL19 to reach the lymphatics
(45,46); both of these molecules are matrix-binding (7), and
the net direction of interstitial ﬂow is always and neces-
sarily toward the nearest draining lymphatic vessel. Inter-
estingly, dendritic cells themselves secrete CCL19 (46),
and it is not known whether tumor cell secretion of
chemokines affects their migration toward lymphatics,
but recent work in our laboratory has shown a connec-
tion between autocrine CCL21 and tumor cell migration
(Shields, J. D., M. E. Fleury, C. Yong, G. J. Randolph, M. A.
Swartz, unpublished material). Thus, one might speculate that
autologous chemotaxis is a mechanism whereby immune
cells and tumor cells migrate toward draining lymphatics.
Additionally, although the calculations have been developed
with matrix-binding morphogens in mind, ECM fragments
themselves have also been shown to serve as a chemotactic
factor—for example, as in the case of ﬁbrin degradation
products (48,49)—and our model predictions are valid for
comparing pericellular gradients of such matrix fragments
as well.
FIGURE 4 Effects of boundary and initial conditions on morphogen gradients for Pe ¼ 0.25. (A) Cell-secreted protease distribution assuming a constant
surface concentration (top row) and corresponding ECM-released morphogen distribution (bottom row) serve as a control for evaluating effects of changing
boundary conditions. Dark red, 1 (maximum concentration); dark blue, 0. (B) The constant surface ﬂux protease condition resulted in a slightly altered cell-
released protease distribution (top row) when compared to the constant concentration boundary case (A); however, the dimensionless ECM-released
morphogen proﬁles shown on the bottom row appear nearly identical. (C) Protease distribution of A, with the resulting ECM-released morphogen proﬁle
calculated assuming that the ECM-bound morphogen was nonuniformly distributed. The ECM-released morphogen gradient (bottom row) shares the same
qualitative shape as for the previous two conditions. (D) Dimensionless ECM-released concentration proﬁles along the bisecting midline of the three cases
shown in A–C are similar.
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In addition to shedding light on a basic phenomenon, this
research may be useful in tissue engineering, whose primary
goal is to recapitulate certain aspects of tissue architecture
function in vitro.Much research has beendevoted to specifying
cell patterns within a matrix, for example by layered two-
dimensional ﬁlms (50), laser-guided ‘‘cellwriting’’ (51), or cell
dielectrophoresis (52). In contrast to such prescriptive designs,
our results demonstrate the potential to engineer 3D tissues
using an appropriate ECM (i.e., one that is growth-factor laden
or rich in binding sites) and introducing physiological dynamic
forces such as interstitial ﬂow to permit synergistic self-
organization to occur. The work presented here may thus serve
as a guide for the rational use of ﬂow andmatrix-binding in con-
trolling morphogen patterning.
In conclusion, our results show that interstitial ﬂow and
matrix-binding morphogens, both physiological conditions,
combine to robustly create asymmetric pericellular morpho-
gen gradients and to amplify them over static conditions in
which the cell secretes active morphogens directly. This mech-
anism may not only help to explain developmental asymme-
try, but it may also 1), serve as an alternative mechanosensing
mechanism for the cell to gather information about the dy-
namic status of its environment, and 2), drive autologous
chemotaxis to help direct migrating cells into tissue-draining
lymphatics.
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